PATENT CLAIM ANALYSIS

Application Number: 16108096
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "186100"]

Abstract:
The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

Claim (Index 48):
The method of  claim 45 , wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, or an antibody cocktail comprising a mixture of at least two anti-EBOV antibodies, is administered prophylactically or therapeutically to the subject in need thereof.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.8
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15005334', '15688474', '15651387', '14717760', '14855274']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8115887415588066
- 35 USC 102 Novelty (BERT): 0.6049979813514289
- Combined Prediction Score: 0.7909296655380689
- Mean Citation Score: 561.514958
- Max Citation Score: 675.2011
- Similarity Product: 451.0431368910611

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test